Cytokinetics (CYTK) vs Spyre Therapeutics (SYRE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Spyre Therapeutics (SYRE) has outperformed Cytokinetics (CYTK) over the past year, gaining 351.9% versus a gain of 2.0%. Over five years, CYTK leads with a +68.1% price change compared with -60.9% for SYRE. Cytokinetics is the larger company by market cap ($8.74 billion vs $7.77 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYTK | SYRE |
|---|---|---|
| Share price | $62.84 | $84.19 |
| Market cap | $8.74B | $7.77B |
| 1-day change | +1.34% | +5.37% |
| YTD return | -2.41% | +143.89% |
| 1-year return | +1.96% | +351.92% |
| 5-year return | +68.09% | -60.93% |
| EPS (TTM) | $-7.22 | $-1.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $88.04M | $0 |
| Revenue growth (YoY) | +376.56% | — |
| Net income (latest FY) | $-784.96M | $-155.20M |
| Operating margin | -695.44% | — |
| Net margin | -891.60% | — |
| 52-week high | $88.31 | $110.18 |
| 52-week low | $54.30 | $18.12 |
| Distance from 52-week high | -28.84% | -23.59% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +74.89% | +42.78% |
| Average volume | 1.97M | 1.22M |
| Shares outstanding | 139.02M | 92.29M |
| Employees | 673 | 125 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SYRE has outperformed CYTK by 350.0 percentage points over the past year.
About Cytokinetics
CYTK stock →Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
Health Care · Biotechnology: Pharmaceutical Preparations · 673 employees
About Spyre Therapeutics
SYRE stock →Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A).
Health Care · Biotechnology: Pharmaceutical Preparations · 125 employees
CYTK vs SYRE FAQ
Which is bigger, Cytokinetics or Spyre Therapeutics?
Cytokinetics (CYTK) is larger, with a market capitalization of $8.74B compared with $7.77B for Spyre Therapeutics (SYRE).
Which stock has performed better over the past year, CYTK or SYRE?
SYRE returned +351.92% over the past 12 months, compared with +1.96% for CYTK (price return, excluding dividends). Past performance does not predict future results.
Are Cytokinetics and Spyre Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.